[go: up one dir, main page]

PE20061296A1 - Un metodo para preparar extractos de ginkgo que tiene un contenido bajo de 4'-o-metil piridoxina y/o biflavonas - Google Patents

Un metodo para preparar extractos de ginkgo que tiene un contenido bajo de 4'-o-metil piridoxina y/o biflavonas

Info

Publication number
PE20061296A1
PE20061296A1 PE2006000392A PE2006000392A PE20061296A1 PE 20061296 A1 PE20061296 A1 PE 20061296A1 PE 2006000392 A PE2006000392 A PE 2006000392A PE 2006000392 A PE2006000392 A PE 2006000392A PE 20061296 A1 PE20061296 A1 PE 20061296A1
Authority
PE
Peru
Prior art keywords
extract
weight
concentrate
content
solution
Prior art date
Application number
PE2006000392A
Other languages
English (en)
Inventor
Clemens Erdelmeier
Hermann Hauer
Friedrich Lang
Egon Koch
Original Assignee
Bioplanta Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplanta Arzneimittel Gmbh filed Critical Bioplanta Arzneimittel Gmbh
Publication of PE20061296A1 publication Critical patent/PE20061296A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11Plant sterols or derivatives thereof, e.g. phytosterols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA OBTENER UN EXTRACTO DE GINKGO BILOBA CON UN CONTENIDO DE MENOS DE 20PPM DE 4'-O-METIL PIRIDOXINA Y/O BIFLAVONAS QUE COMPRENDE: A) OBTENER EL EXTRACTO DE LAS HOJAS DE GINKGO BILOBA UTILIZANDO ACETONA CON AGUA, UN ALCANOL O METANOL ANHIDRO; B) SEPARAR EL SOLVENTE ORGANICO CONCENTRANDO EL SOLVENTE HASTA OBTENER UN CONTENIDO DE 10% EN PESO; C) DILUIR LA SOLUCION ACUOSA REMANENTE CON AGUA HASTA OBTENER UN CONTENIDO DE SOLIDOS DE ENTRE 5% Y 25% EN PESO, ENFRIAR A UNA TEMPERATURA MENOR DE 25ºC Y DEJAR EN REPOSO HASTA LA FORMACION DE UN PRECIPITADO; D) TRATAR LA SOLUCION ACUOSA REMANENTE CON SULFATO DE AMONIO, LUEGO REALIZAR UNA EXTRACCION CON METIL ETIL CETONA O UNA MEZCLA DE METIL ETIL CETONA Y ACETONA; E) CONCENTRAR EL EXTRACTO OBTENIDO Y DILUIR CON UNA MEZCLA DE ETANOL Y AGUA PARA OBTENER UNA SOLUCION QUE CONTIENE 50% EN PESO DE AGUA Y 50% EN PESO DE ETANOL, CON UN CONTENIDO DE SOLIDOS DE 10% EN PESO; F) TRATAR LA SOLUCION CON UN COMPUESTO DE PLOMO O UNA POLIAMIDA INSOLUBLE; G) EXTRAER LA SOLUCION FILTRADA CON UN SOLVENTE ALIFATICO O CICLOALIFATICO; H) CONCENTRAR LA SOLUCION ACUOSA ALCOHOLICA REMANENTE, REALIZAR UN TRATAMIENTO CON SULFATO DE AMONIO Y UNA EXTRACCION CON METIL ETIL CETONA Y ETANOL; I) CONCENTRAR LA FASE ORGANICA J) DISOLVER EL CONCENTRADO; K) FILTRAR SOBRE UNA RESINA DE ADSORCION; Y M) SECAR EL CONCENTRADO A PRESION REDUCIDA. DICHO EXTRACTO ES UTIL PARA EL TRATAMIENTO DE DEMENCIA, TRASTORNOS DE LA CIRCULACION SANGUINEA CEREBRAL
PE2006000392A 2005-05-03 2006-04-17 Un metodo para preparar extractos de ginkgo que tiene un contenido bajo de 4'-o-metil piridoxina y/o biflavonas PE20061296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005020685 2005-05-03
DE102005061948A DE102005061948A1 (de) 2005-05-03 2005-12-23 Verbessertes Verfahren zur Herstellung von 4'-O-Methylpyridoxin- und/oder Biflavon-armen Ginkgoextrakten

Publications (1)

Publication Number Publication Date
PE20061296A1 true PE20061296A1 (es) 2007-01-06

Family

ID=36693938

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000392A PE20061296A1 (es) 2005-05-03 2006-04-17 Un metodo para preparar extractos de ginkgo que tiene un contenido bajo de 4'-o-metil piridoxina y/o biflavonas

Country Status (26)

Country Link
US (2) US20060251746A1 (es)
EP (1) EP1868625B1 (es)
JP (2) JP4304230B2 (es)
KR (1) KR100933721B1 (es)
CN (2) CN101175505A (es)
AR (1) AR054270A1 (es)
AT (1) ATE401903T1 (es)
AU (1) AU2006243378B2 (es)
BR (1) BRPI0611093B1 (es)
CA (1) CA2606843C (es)
DE (2) DE102005061948A1 (es)
DK (1) DK1868625T3 (es)
DO (1) DOP2006000091A (es)
ES (1) ES2310408T3 (es)
JO (1) JO2523B1 (es)
MX (1) MX2007013398A (es)
MY (1) MY143650A (es)
NZ (1) NZ563818A (es)
PE (1) PE20061296A1 (es)
PL (1) PL1868625T3 (es)
PT (1) PT1868625E (es)
RU (1) RU2367459C2 (es)
SI (1) SI1868625T1 (es)
TW (1) TWI376230B (es)
UA (1) UA84519C2 (es)
WO (1) WO2006117169A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709633T3 (es) * 2007-12-21 2019-04-17 Dr Willmar Schwabe Gmbh & Co Kg Uso de un extracto de hojas de Ginkgo biloba
EP2494979B1 (de) 2011-03-04 2019-03-27 Dr. Willmar Schwabe GmbH & Co. KG Verwendung von Extrakten aus Blättern von Ginkgo biloba zur Prävention und Therapie von Komplikationen nach operativer Arteriosklerose-Behandlung sowie von Folgeerscheinungen der Arteriosklerose
MX341428B (es) 2011-04-27 2016-08-18 Dr Willmar Schwabe Gmbh & Co Kg Tableta de liberacion controlada de extracto de ginkgo biloba y procedimiento para su obtencion.
DE102014202318B4 (de) * 2014-02-10 2016-10-06 Dr. Willmar Schwabe Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Ginkgoextrakten
CN103919768B (zh) * 2014-03-30 2016-03-16 吴静 一种含有异银杏双黄酮和白果内酯的药物组合物及其制剂
CN107509997B (zh) * 2017-09-08 2021-02-26 南京林业大学 一种基于内源糖苷酶酶解结合树脂吸附脱除白果致毒成分的方法及其制备的产品和应用
CN107647407A (zh) * 2017-11-14 2018-02-02 宜昌东方昌绿茶业有限公司 一种从银杏茶中提取黄酮素的方法
CN113491721B (zh) * 2020-03-19 2022-05-31 江苏得乐康生物科技有限公司 一种脱除银杏叶提取物中银杏毒素的方法
CN115894424B (zh) * 2023-01-06 2023-05-12 中日友好医院(中日友好临床医学研究所) 新型双黄酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627387B1 (fr) * 1988-02-24 1992-06-05 Fabre Sa Pierre Procede d'obtention d'un extrait de feuilles de ginkgo biloba
GB8822004D0 (en) * 1988-09-20 1988-10-19 Indena Spa New extracts of ginkgo biloba & their methods of preparation
DE3940091A1 (de) * 1989-12-04 1991-06-06 Schwabe Willmar Gmbh & Co Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel
JP3518882B2 (ja) 1993-11-12 2004-04-12 ダイセル化学工業株式会社 イチョウエキス及びその製造法
DE19756848C2 (de) * 1997-12-19 2003-01-16 Schwabe Willmar Gmbh & Co Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen
US20040076691A1 (en) * 2002-01-16 2004-04-22 David Haines Anti-inflammatory formulations
CN1251675C (zh) * 2004-02-10 2006-04-19 张正生 一种注射用银杏达莫粉针剂及其制备方法
CN100451013C (zh) * 2004-04-21 2009-01-14 徐州技源天然保健品有限公司 一种从卷柏中提取穗花杉双黄酮提取物的生产工艺

Also Published As

Publication number Publication date
JO2523B1 (en) 2010-03-17
WO2006117169A1 (en) 2006-11-09
EP1868625A1 (en) 2007-12-26
US20060251746A1 (en) 2006-11-09
RU2007143632A (ru) 2009-06-10
KR20070112271A (ko) 2007-11-22
DK1868625T3 (da) 2008-11-10
DOP2006000091A (es) 2007-01-31
TW200716149A (en) 2007-05-01
RU2367459C2 (ru) 2009-09-20
US8642099B2 (en) 2014-02-04
DE602006001949D1 (de) 2008-09-04
SI1868625T1 (sl) 2008-12-31
JP4304230B2 (ja) 2009-07-29
ES2310408T3 (es) 2009-01-01
AU2006243378A1 (en) 2006-11-09
PT1868625E (pt) 2008-09-22
MX2007013398A (es) 2007-12-07
TWI376230B (en) 2012-11-11
JP2009173663A (ja) 2009-08-06
BRPI0611093A2 (pt) 2010-08-10
NZ563818A (en) 2009-11-27
ATE401903T1 (de) 2008-08-15
CN104189025A (zh) 2014-12-10
AR054270A1 (es) 2007-06-13
JP2008540354A (ja) 2008-11-20
PL1868625T3 (pl) 2009-01-30
UA84519C2 (ru) 2008-10-27
AU2006243378B2 (en) 2008-03-20
CA2606843C (en) 2010-05-25
CN101175505A (zh) 2008-05-07
EP1868625B1 (en) 2008-07-23
US20080286391A1 (en) 2008-11-20
KR100933721B1 (ko) 2009-12-24
CA2606843A1 (en) 2006-11-09
MY143650A (en) 2011-06-30
BRPI0611093B1 (pt) 2018-01-16
DE102005061948A1 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
PE20061296A1 (es) Un metodo para preparar extractos de ginkgo que tiene un contenido bajo de 4'-o-metil piridoxina y/o biflavonas
AR121861A2 (es) MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA
KR101788099B1 (ko) 은행나무 추출물의 개선된 제조방법
BR0307330A (pt) Produção do delta-9-tetraidrocanabinol
BR112018012314B1 (pt) Método para síntese de ácido, e, métodos para preparar um quelato de dota metálico e gadoterato de meglumina
CN104844447B (zh) 一种以藤黄果为原料制备高纯度羟基柠檬酸的方法
Gallardo et al. Effect of intracerebral hydroxytyrosol and its nitroderivatives on striatal dopamine metabolism: A study by in vivo microdialysis
US9139551B2 (en) Preparation of a new class of water-soluble ammonium 2,3-dihydroxy-5-((2R,3R)-3,5,7-trihydroxy-4-oxochroman-2-yl) phenolates and their biological activity of alcohol elimination
CN101775023B (zh) 从骆驼刺植物中提取的异黄酮木脂素类化合物及其用途和提取方法
CN102229594A (zh) 一种双水相体系纯化远志呫吨酮类化合物的方法
Onda et al. Ionic liquid-mediated extraction of bilobalide from Ginkgo biloba leaves
WO2006061855A3 (en) Salts assisted selective extraction of 6-acetyl-4.1', 6' trichlorogalactosucrose and 4, 1 ', 6' trichlorogalactosucrose from aqueous reaction mixture
CA3133547C (en) Liquid-liquid extraction of purified psychoactive alkaloid
CN104561220A (zh) 一种采用纤维素酶水解番茄枝叶制备番茄碱的方法
DE50203442D1 (de) Aufarbeitung der bei der Herstellung von hochreinem Triethylendiamin anfallenden Mutterlauge
US20140005373A1 (en) Method of extracting kaempferol-based antioxidants from solenostemma arghel
RU93041052A (ru) Способ получения монозамещенной аммонийной соли глицирризиновой кислоты
TH74890A (th) วิธีการทำเพื่อใช้ในการเตรียมสารสกัดกล้วย
CN105622611A (zh) 一种从茶叶中提取咖啡因的方法
Parameshappa et al. STUDIES ON NEPHROPROTECTIVE ACTIVITY OF TEPHROSIA PURPURIA LINN ALCOHOLIC EXTRACT BY CISPLATIN INDUCED MODEL USING ALBINO RATS
Jakovljević Kovač et al. Assessment of antibacterial and antiradical activity in Alchemilla vulgaris L. extract treated with macroporous resins
Anderson The determination of Beta-Substituted Glutarimides in blood: time-concentration curves after intravenous administration of two barbiturate antagonists
CN107056780A (zh) 硫辛酸‑他克林类似基团异二联体及其治疗阿尔兹海默症的应用
VAEZIKAKHKI et al. Antioxidant activity of iron nanoparticles synthesized from aqueous extract of Saponaria officinalis
Couch Lupine Studies. XV. 1 The Alkaloids of Lupinus sericeus Pursh

Legal Events

Date Code Title Description
FG Grant, registration